CSL Ltd
(ASX:CSL) has today upgraded its net profit after tax (NPAT) forecast for this financial year.
In August 2016, the biotechnology company announced it was expecting 11% NPAT growth.
Now, the company expects its NPAT to grow between 18% to 20% at constant currency basis on its FY16 result. This takes into account one-off gains and costs associated with CSL’s acquisition of the Novartis influenza vaccines business.
CSL is also expecting to report NPAT of around US$800 million for six months ended 31 December 2016. However, this result includes a currency exchange headwind of around US$20 million.
CSL posted a net profit of $1.7 billion at 30 June 2016.
